At Janssen, our fight against infectious diseases is a global effort. From viral hepatitis and human immunodeficiency virus (HIV) to pathogens of global concern. We strive to discover and develop novel therapeutics and vaccines to help prevent, treat and utlimately cure infectious diseases worldwide, improving treatment outcomes and patients’ lives.
With goals like these, there’s no time to waste. That’s why the team focuses on internal discovery and world-class development of therapeutics and vaccines whilst seeking out partnerships across the world to connect our expertise with others. We believe these problems can be conquered the same way all of humanity’s greatest problems have been solved: persistent effort and game-changing innovation.
We envision a world where cancer is a preventable, chronic or curable disease. To get there, we’re focused on pursuing new pathways that can help to prolong and improve patient lives.
In Oncology, our goal is to fundamentally alter the way cancer is understood, diagnosed, and managed. One of the innovative ways that we approach this challenge is via cancer interception. We are striving to achieve a more robust understanding of the mechanisms underlying the transition of normal cells to a pre-malignant state, with the goal of developing products capable of intercepting cancer at its earliest stages, when patients are healthier and more likely to benefit.
Over the past decade, Janssen has redefined the standard of care in immunology. With a rich heritage in developing cutting-edge treatments that can help to address the needs of millions of patients living with autoimmune and inflammatory diseases. Janssen strives to change the way diseases are treated; pursuing new pathways that could prevent, intercept and ultimately cure, and expanding our portfolio beyond monoclonal antibodies to include novel, oral small molecules and new biologic platforms. Through our ongoing efforts in discovery, biomarkers, clinical research and external innovation, we are poised for continued leadership, bringing transformational medicines to patients and healthcare providers to achieve our vision: a world free from immune diseases.
At Janssen, we are focused on pushing the boundaries of medicine- to help resolve some of the most challenging medical conditions of our time. Mental health has been an important part of our heritage since our company was founded and we remain committed to reducing the burden, disability and devastation caused by mental health disorders.
We continue to invest in expanding treatment options, even as many companies have moved away from neuroscience because of its complexity and risk. We are immensely proud of the many ground-breaking mental health products Janssen has pioneered over the course of our 60+ year legacy in field.
The integration of Actelion into the Janssen Pharmaceutical Companies of Johnson & Johnson in 2017, saw PH established as our sixth disease area strong hold. We aim to build upon the strong heritage of Actelion, where in the past two decades, the prognosis and quality of life for people with PH has significantly improved.
Together, we have a clear strategy to transform lives through closing the diagnosis gap and building an innovative pipeline. Janssen is committed to improving PH patient outcomes for the long haul. This means holistically addressing unmet needs across the patient journey, including faster diagnosis, better monitoring and new treatment approaches, including novel therapeutic devices, digital health solutions and non-invasive diagnostics to aid faster referral to specialist care.
Janssen has an enduring commitment to researching the prevention and treatment of cardiovascular and metabolic diseases. Our aim is to develop innovative healthcare solutions that will significantly improve outcome for patients. As such, we are building a comprehensive approach to diabetes care as well as cardiovascular disease, uncovering new therapies we hope will improve the quality of life for patients.
Our mission is global, local and personal. Together, we can reshape the future of cardiovascular and metabolic disease prevention and treatment.
Ortho-Gynol was introduced in 1931 as the first prescription family planning product from the Ortho Products operating unit. This pioneering contraceptive gel was based on the need for trusted family planning products.
HALDOL® (haloperidol) was discovered by Janssen Pharmaceutica, N.V. in 1960. Patients taking HALDOL® could be treated at home instead of in an institution. It became the gold standard for treating schizophrenia for more than 25 years.
Ortho Pharmaceutical introduces the second oral contraceptive available in the United States (Ortho-Novum 10 and Ortho-Novum 2, produced by Syntex).
Ortho Diagnostic Systems introduces RhoGAM Rho(D) immune globulin, the first medication developed to prevent Rh hemolytic disease of the newborn.
We introduced a cell line technology that enables faster and most cost effective discovery, development and production of a range of potentially transformational vaccines and monoclonal antibodies.
PROCRIT®, approved by the U.S. FDA for use in 1989, is a prescription medicine used to treat certain types of anemia.
Centocor, now part of Janssen Biotech Inc., introduces REMICADE®, a prescription medication used to treat many auto-immune conditions, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis and plaque psoriasis.
AdVac® technology, based on the development and production of adenovirus vectors is introduced. It can be used to develop vaccines against life-threatening infectious diseases such as Ebola.
Established in celebration of the legacy of “Dr. Paul” and in recognition of current researchers demonstrating a similar spirit, the Dr. Paul Janssen Award was first presented in 2006.
ZYTIGA®, a prescription medication used in combination with prednisone to treat men with metastatic castration-resistant prostate cancer, is introduced.
DARZALEX® (daratumumab) injection for intravenous infusion is indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy.